Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Adicet Bio (NASDAQ: ACET) is a biotechnology company founded in 2014 and headquartered in Redwood City, California. The company specializes in developing off-the-shelf allogeneic gamma delta T cell therapies, focusing on creating genetically modified gamma delta T cells that selectively target tumors. This innovative approach offers a new generation of universal immune cell therapy for cancer treatment, primarily serving the healthcare sector.
Since its inception, Adicet Bio has made significant strides in the field of cancer treatment, raising a total of $131 million in funding. The company's commitment to advancing cancer therapies through its unique approach to immune cell therapy has positioned it as a notable player in the biotechnology industry.
As of now, there is no concrete information available regarding Adicet Bio's IPO prospects. The company is already publicly traded on the NASDAQ under the ticker symbol ACET, which means it has already completed its initial public offering. For investors interested in Adicet Bio stock or looking to buy Adicet Bio shares, the company's current public status allows for direct investment through traditional stock market channels.
It's important to note that any future financial decisions or changes in the company's public status would be subject to various factors, including market conditions, company performance, and regulatory requirements. As always, potential investors should conduct thorough research and consult with financial advisors before making investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Adicet Bio's IPO prospects remain uncertain, investors eager to gain exposure to promising biotechnology companies don't have to wait. At Linqto, we offer members access to interests in pre-IPO private companies, including potential leaders in the biotech sector. Our platform allows you to diversify your portfolio with lower minimum investments in emerging industry innovators like Adicet Bio, potentially benefiting from their growth before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
